Comparative Pharmacology
Head-to-head clinical analysis: SAMSCA versus VAPRISOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SAMSCA versus VAPRISOL.
SAMSCA vs VAPRISOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective vasopressin V2 receptor antagonist; increases free water excretion, resulting in aquaresis and increased serum sodium concentration.
Selective vasopressin V2 receptor antagonist; inhibits water reabsorption in the collecting duct of the kidney, promoting aquaresis without affecting electrolyte excretion.
15 mg orally once daily, increased to 30 mg once daily after 24 hours as needed, maximum 60 mg once daily.
Initial dose: 20 mg IV over 30 minutes, then continuous IV infusion at 20 mg/day for 2-4 days; may increase to 40 mg/day if inadequate response. Maximum duration: 4 days.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours in healthy subjects; prolonged in hepatic impairment (up to 20 hours) and heart failure (up to 20 hours).
Terminal elimination half-life is approximately 6.5 to 8 hours in patients with normal renal and hepatic function; may be prolonged in hepatic impairment.
Primarily metabolized by CYP3A4; <1% excreted unchanged in urine. 80% of dose excreted in feces, 20% in urine as metabolites.
Primarily hepatic metabolism, with approximately 99% of the dose recovered in feces via biliary excretion and less than 1% excreted unchanged in urine.
Category C
Category C
Vasopressin Receptor Antagonist
Vasopressin Receptor Antagonist